MAP2K7 and melanoma: A multi‐drug phase II clinical trial including pan‐FGFR inhibitor (BGJ398) together with a MEK inhibitor (MEK162) and a RAF inhibitor (LGX818) is currently ongoing in advanced BRAF melanoma (NCT02159066).